Author

Amelia Gabler

Observed names: A Gabler, A.R. Gabler, Amelia R. Gabler

Institutions: Johns Hopkins University, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

Observed institutions: Memorial Sloan Kettering Cancer Center, Johns Hopkins University, Heidelberg University, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

OpenAlex ID: A5087487609

Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia

2002 · RF Schlenk, F Hartmann, et al. · Leukemia · 19

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma.

2019 · Yelena Yuriy Janjigian, Steven Brad Maron, et al. · Journal of Clinical Oncology · 16

Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer

2019 · Ryan H. Moy, Gustavo Dos Santos Fernandes, et al. · The Oncologist · 11

Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

2020 · John Mascarenhas, Heidi E. Kosiorek, et al. · Blood · 10

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma

2019 · Y.Y. Janjigian, S. Maron, et al. · Annals of Oncology · 9

Works count: 5

Citation count: 65

H-index: 5

I10-index: 4